Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Lilly’s Zepbound beats Novo’s Wegovy in head-to-head trial #shorts #zepbound #wegovy
Posted
December 4, 2024
Views
5,295
Likes
60
Comments
2
Engagement
December 4, 2024
5,295
60
2
1.17%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
0:44Now PlayingEli Lilly said its weightloss drug Zepbound outperformed rival Novo Nordisk's Wegovy in the first headtohead trial of the two blockbusters. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke to Bloomberg TV about the results
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
